Clinical trials: SARS-COV2 Virus
SARS-CoV-2 Infection
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More
This is a phase 2, randomized, observer-blinded, placebo-controlled clinical study to evaluate the immunogenicity and safety of SARS-CoV-2 mRNA Vaccine (SYS6006）in healthy participants aged 18 or more.
- Trial name
- NCT05439824
- Testing
- SYS6006 20 μg, SYS6006 30 μg
- Where
- 2 sites in China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years
The study is a randomized, double-blind Phase II study. It will evaluate the immunogenicity and safety of SCTV01E-1. Approximately 400 participants aged 18 years and older will be enrolled in this study.
- Trial name
- NCT05522829
- Testing
- SCTV01E-1 on D0, SCTV01E-1 on D28, SCTV01E-1 on D150
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19
A Study to Evaluate the Ability of UB-612 COVID-19 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines.
This is a study to evaluate the ability of UB-612 vaccine to boost immunity of subjects who previously received two doses of AstraZeneca COVID-19 vaccine (ChAdOx1-S) with an 8-16 week interval between first and second doses.
- Trial name
- NCT05167253
- Testing
- UB-612
- Volunteers
- healthy volunteers welcome
- Sponsor
- United Biomedical Inc., Asia
COVID-19, SARS-CoV-2 Acute Respiratory Disease
Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.
This Phase IIb clinical study aims to compare the immunogenicity and safety of a booster dose of recombinant protein RBD fusion dimer vaccine as a heterologous booster (to subjects who have received the second dose of the…
- Trial name
- NCT05142553
- Testing
- COVID-19 Vaccine HIPRA, Cominarty (Pfizer-BioNtech)
- Where
- 10 sites in Spain
- Volunteers
- 887 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
COVID-19, Influenza
A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine
This is a randomized, observer-blinded, Phase 2 study evaluating the safety and immunogenicity of a severe acute respiratory syndrome coronavirus 2 (SARSCoV2) recombinant spike (rS) (SARS-CoV-2 rS) nanoparticle and quadrivalent…
- Trial name
- COVID-19 (NCT05519839)
- Testing
- qNIV Vaccine with Matrix-M Adjuvant, Influenza Vaccine, CIC Vaccine with Matrix-M Adjuvant
- Where
- 35 sites in Australia, New Zealand
- Volunteers
- 1,579 people, healthy volunteers welcome
- Sponsor
- Novavax
SARS-CoV2 Infection
Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine
This phase III trial aims to assess the efficacy, safety and immunogenicity of SARS-CoV-2 Vaccine (inactivated) and lot-to-lot consistency evaluation
- Trial name
- COVID-19 (NCT04508075)
- Testing
- SARS-CoV-2 vaccine (inactivated)
- Where
- Indonesia
- Volunteers
- 1,620 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Covid-19
CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients
This is a phase 3, randomized, placebo controlled, double-blind, multicenter, stratified study of CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately symptomatic hospitalized Covid-19 patients with…
- Trial name
- NCT04734873
- Testing
- CPI-006 2 mg/kg + SOC, CPI-006 1 mg/kg + SOC
- Where
- 91 sites in United States, Argentina and 10 more
- Volunteers
- 46 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
SARS-CoV-2 Infection, COVID-19
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years
The study is a randomized, double-blind, positive-controlled Phase II booster study. It will evaluate the immunogenicity and safety of SCTV01E compared with Comirnaty.
- Trial name
- NCT05329051
- Testing
- SCTV01E, Comirnaty
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Covid19
The Prevent Severe COVID-19 (PRESECO) Study
Double-blinded, placebo control, randomized, phase-3 clinical trial to evaluate clinical efficacy of Favipiravir in patients with mild to moderate symptoms related to COVID-19 infection
- Trial name
- PRESECO (NCT04600895)
- Testing
- Favipiravir
- Where
- 38 sites in United States, Brazil and 1 more
- Volunteers
- 1,187 people
- Sponsor
- Appili Therapeutics Inc.
COVID-19
Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (SARS-CoV-2) from…
- Trial name
- APLICOV-PC (NCT04382066)
- Testing
- Plitidepsin 1.5 mg/day, Plitidepsin 2.0 mg/day, Plitidepsin 2.5 mg/day
- Where
- 13 sites in Spain
- Volunteers
- 46 people
- Sponsor
- PharmaMar
SARS-CoV-2 Infection, COVID-19
A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults
This study will compare the safety and tolerability of lyophilized BNT162b2 presented in single dose vials to those of frozen-liquid BNT162b2 in multidose vials and determine whether the immune response is noninferior.
- Trial name
- NCT04816669
- Testing
- BNT162b2
- Where
- 21 sites in United States
- Volunteers
- 629 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19
Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19
Sotrovimab binds to a conserved epitope on the severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 spike protein outside the receptor-binding motif and has been shown to reduce the risk of hospitalization…
- Trial name
- LUNAR (NCT05305651)
- Testing
- Sotrovimab
- Where
- 8 sites in United Kingdom
- Volunteers
- 217 people
- Sponsor
- GlaxoSmithKline
COVID - 19, Influenza A
Evaluation of COVID-19 and Flu A/B 3 in 1 Combo Rapid Test
This observational study aims to evaluate the diagnostic performance of an investigational Influenza A/B and COVID-19 test in patients presenting with signs and symptoms of respiratory infection.
- Conditions
- COVID - 19, Influenza A, Influenza B
- Trial name
- NCT07190131
- Testing
- Investigational Flu A/B And Covid-19 Diagnostic Test
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 588 people
- Sponsor
- iHealth Labs inc
Covid19
Estetrol (E4) for the Treatment of Patients With Confirmed SARS-COV-2 Infection
It has been reported in several research studies that men are almost twice as likely to progress to severe COVID 19 disease and die than women.
- Trial name
- NCT04801836
- Testing
- Estetrol monohydrate 15 mg
- Where
- 25 sites in Belgium, Hungary and 2 more
- Volunteers
- 162 people
- Sponsor
- NEURALIS s.a.
COVID-19
Phase Ⅱ and Ⅲ Trial of a SARS-CoV-2 Vaccine LYB001
The phase Ⅱ trial adopts a randomized, double-blind, placebo-controlled design to evaluate the immunogenicity and safety profile of LYB001 in healthy adults aged 18 years and older.
- Trial name
- NCT05137444
- Testing
- LYB001
- Volunteers
- 1,900 people, healthy volunteers welcome
- Sponsor
- Yantai Patronus Biotech Co., Ltd.
COVID-19, COVID-19 Pandemic
Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis
The purpose of this retrospective study is to evaluate the effectiveness of CPM nasal spray as part of the treatment of COVID-19 and its impact on clinical symptoms. Two cohort groups will be compared (CPM vs. standard care).
- Conditions
- COVID-19, COVID-19 Pandemic, COVID-19 Respiratory Infection, SARS CoV 2 Infection
- Trial name
- ACCROS-R (NCT05520944)
- Testing
- ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray
- Where
- Dominican Republic
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Dr. Ferrer BioPharma
Mild to Moderate COVID-19
Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19
This study is a double-blind,randomized,placebo-controlled study to evaluate the efficacy and safety of FB2001 for Inhalation in patients with mild to moderate Coronavirus Disease 2019(COVID-19).
- Trial name
- NCT05675072
- Testing
- FB2001
- Where
- China
- Volunteers
- 1,336 people
- Sponsor
- Frontier Biotechnologies Inc.
SARS-CoV-2 Infection, Coronavirus Disease 2019 (COVID-19)
COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older
The most recently discovered coronavirus (SARS-CoV-2) may cause illness in humans ranging from the common cold to serious illness, also referred to as Coronavirus disease 2019 (COVID-19).
- Trial name
- CV-NCOV-011 (NCT04848467)
- Testing
- SARS-CoV-2 mRNA Vaccine (CVnCoV), Quadrivalent influenza vaccine (QIV)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bayer
Sars-CoV-2, Covid19
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects
BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9 that is selective over the cathepsins as well as other protease families, displays good metabolic stability and permeability…
- Trial name
- NCT04334460
- Testing
- BLD-2660
- Where
- 35 sites in United States, Brazil
- Volunteers
- 120 people
- Sponsor
- Blade Therapeutics
COVID-19
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)
A Phase I clinical study to evaluate the safety, tolerability, and immunogenicity of SARS-CoV-2 variant (Omicron) mRNA vaccine which is used to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2…
- Trial name
- NCT05433194
- Testing
- ABO1009-DP
- Where
- United Arab Emirates
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.